JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Fulgent Genetics Inc

Fechado

SetorSaúde

23.6 0.64

Visão Geral

Variação de preço das ações

24h

Atual

Mín

23

Máximo

23.74

Indicadores-chave

By Trading Economics

Rendimento

-7.4M

-19M

Vendas

8.3M

82M

Margem de lucro

-23.539

Funcionários

1,313

EBITDA

-3.5M

-15M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+7.79% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

181M

730M

Abertura anterior

22.96

Fecho anterior

23.6

Sentimento de Notícias

By Acuity

50%

50%

163 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Fulgent Genetics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de out. de 2025, 20:49 UTC

Ganhos

Correction to Thermo Fisher Article on Oct. 22

23 de out. de 2025, 23:51 UTC

Conversa de Mercado

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 de out. de 2025, 23:49 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

23 de out. de 2025, 23:49 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 de out. de 2025, 23:37 UTC

Conversa de Mercado

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 de out. de 2025, 22:58 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

23 de out. de 2025, 22:57 UTC

Conversa de Mercado

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 de out. de 2025, 22:49 UTC

Aquisições, Fusões, Aquisições de Empresas

How Trump Sparked a New Era of State Capitalism -2-

23 de out. de 2025, 22:49 UTC

Aquisições, Fusões, Aquisições de Empresas

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 de out. de 2025, 22:17 UTC

Ganhos

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 de out. de 2025, 21:41 UTC

Ganhos

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 de out. de 2025, 21:05 UTC

Ganhos

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 de out. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

23 de out. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

23 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

23 de out. de 2025, 20:35 UTC

Ganhos

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 de out. de 2025, 20:28 UTC

Ganhos

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 de out. de 2025, 20:15 UTC

Conversa de Mercado
Ganhos

Global Commodities Roundup: Market Talk

23 de out. de 2025, 20:10 UTC

Ganhos

Newmont Mining 3Q Adj EPS $1.71

23 de out. de 2025, 20:10 UTC

Ganhos

Newmont Mining 3Q Sales $5.52B

23 de out. de 2025, 20:10 UTC

Ganhos

Newmont Mining 3Q EPS $1.67

23 de out. de 2025, 20:09 UTC

Ganhos

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 de out. de 2025, 20:07 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

23 de out. de 2025, 20:07 UTC

Conversa de Mercado
Ganhos

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 de out. de 2025, 20:07 UTC

Ganhos

Blackstone Looks to IPOs for Investment Exits -- Update

23 de out. de 2025, 20:05 UTC

Ganhos

Intel 3Q Gross Margin 38.2% >INTC

23 de out. de 2025, 20:04 UTC

Ganhos

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 de out. de 2025, 20:04 UTC

Ganhos

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 de out. de 2025, 20:04 UTC

Ganhos

Intel: 4Q Guidance Excludes Altera >INTC

23 de out. de 2025, 20:04 UTC

Ganhos

Intel Sees 4Q Adj EPS 8c >INTC

Comparação entre Pares

Variação de preço

Fulgent Genetics Inc Previsão

Preço-alvo

By TipRanks

7.79% parte superior

Previsão para 12 meses

Média 25.33 USD  7.79%

Máximo 30 USD

Mínimo 21 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Fulgent Genetics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

3 ratings

2

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

17.32 / 19.04Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Neutral Evidence

Sentimento

By Acuity

163 / 371 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
help-icon Live chat